The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis.
about
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyondAdvanced therapies for end-stage heart failureThe cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fractionClinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failureEffects of Low-Dose Recombinant Human Brain Natriuretic Peptide on Anterior Myocardial Infarction Complicated by Cardiogenic Shock.Inotropes do not increase mortality in advanced heart failureRenal Function and Outcomes With Use of Left Ventricular Assist Device Implantation and Inotropes in End-Stage Heart Failure: A Retrospective Single Center Study.Nitroxyl (HNO): A novel approach for the acute treatment of heart failureDyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study.Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study.Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling.Acute decompensated heart failure update.Inotropic agents use in patients hospitalized with acute decompensated heart failure: a retrospective analysis from a 22-year registry in a Middle-Eastern Country (1991-2013).Interrogating a clinical database to study treatment of hypotension in the critically ill.An emerging role for calcium sensitisation in the treatment of heart failure.Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE.An overview of inotropic agents.Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology.Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.Medical support and surgery of the failing heart: levosimendan.Novel cardiac myosin activators for acute heart failure.Modern approach to the treatment of decompensated heart failure.Newer treatments for decompensated heart failure: focus on levosimendan.Decision making in advanced heart failure: a scientific statement from the American Heart AssociationShock in acute myocardial infarction: the Cape Horn for trials?Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents.Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials.Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure.Causes and treatment of oedema in patients with heart failure.Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.Repetitive infusion of levosimendan in patients with chronic heart failure: a meta-analysis.Autonomic Dysregulation as a Therapeutic Target for Acute HF.Heart calcium sensitizer on morbidity and mortality of high-risk surgical patients with MODS: systematic review and meta-analysis.Long-term intravenous inotropes in low-output terminal heart failure?New pharmacological approaches in heart failure therapy: developments and possibilities.Pharmacological and Non-pharmacological Treatment for Decompensated Heart Failure: What Is New?Update on the Management of Acute Decompensated Heart Failure.Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study.Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study.
P2860
Q24645066-8F87DF92-2472-4DCE-A8FD-7A137F2EC303Q26992073-220CCF02-8001-470D-AB4C-D0E6BF0840C8Q27024279-04CD2143-759B-4902-A2BD-F6F2B06DFC3DQ28168872-189CDE85-B56E-4939-A325-883086715F47Q33615284-6DCB83E6-DB6B-403E-A43A-79A0F151FAADQ33685748-EC4464E3-3142-4137-B7E1-B567A8E74057Q33763311-269D9AD4-C39E-469E-95EA-A5C42B1D8BB7Q33946688-BF622D0F-0168-4578-A4B0-A09A190766C1Q34148325-7481AFE9-2B45-4D96-AC64-3BF16C575188Q34565386-6671FB2C-253A-4B6A-85C0-74B788E6A98AQ34983537-0F93325C-FCC5-4C11-9C11-2B4D982B1971Q35139964-CE41CB70-A59F-4611-8506-07B3174EDBDBQ35927894-CC22394D-6FC4-4679-895F-BFAFA4A34039Q36021295-9FE3BE76-67EE-4071-AB3E-BC5946453855Q36187050-9E603E9D-1A1F-4FAE-80B8-E9714F9FF8D6Q36357779-FAD72ACB-56F5-413E-9C29-0CF2927B4650Q36588715-3856EDC9-E425-4EF4-AA7B-2B9C654F8BABQ36811824-E71A0800-A3BF-4895-A239-75B3F111A2DAQ36832816-BBCC1A24-B527-4234-991A-EA55AC4DD9CFQ36902537-C0777DA2-2A5D-463A-93A6-99E1AF1FA9EAQ36964682-5189894C-0D5F-401B-80C8-2FFAE741BB3BQ37390754-BDF20537-8B60-47F1-A37B-8CAD75109BDAQ37403197-E378A74C-277C-4177-AEE6-8919FE773C03Q37486284-806AD5FD-6868-40AB-8F5D-35D738FF411BQ37770822-90D7602D-512E-4B5F-AF54-7B2A0284A457Q37858515-9CA60759-C595-4E16-9402-018ECD599E57Q37886295-F914998F-2673-4581-9A87-E409252A0EFBQ38009708-FA52F1C0-875F-4A99-B857-4027AB96FA70Q38074093-8F773096-64CD-4D2A-BF88-D6C4366423D8Q38099679-539A5DFC-4792-467F-B792-3455A90D0AC8Q38173852-FA1D233F-7F32-4226-BB78-AD7C78C9BA4CQ38391855-79D8957F-22A6-45C8-8E94-CB7F5CBB67DCQ38573100-18E12C14-C2BF-4E5C-9771-B42B83FDF010Q38697549-D51057EC-0AE4-41DB-8C8C-FD3714F5B5AFQ38734731-91BF010E-D2D0-4A26-80B8-843FB70EFA6BQ38759494-C13174C0-F2F7-459A-A3FD-0874F7E2F5BDQ39249844-627580F8-64A1-4B8C-B525-DA091DD1D344Q39258163-BC035761-FEA1-4520-82E1-79725D67CFDFQ39269611-CD7575B7-2766-4C18-A14D-F14DDF5F1BF9Q39289569-5FC8C879-47BB-49A4-B668-A2DEB76126CF
P2860
The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The effectiveness and relative ...... re-a meta-regression analysis.
@ast
The effectiveness and relative ...... re-a meta-regression analysis.
@en
The effectiveness and relative ...... re-a meta-regression analysis.
@nl
type
label
The effectiveness and relative ...... re-a meta-regression analysis.
@ast
The effectiveness and relative ...... re-a meta-regression analysis.
@en
The effectiveness and relative ...... re-a meta-regression analysis.
@nl
prefLabel
The effectiveness and relative ...... re-a meta-regression analysis.
@ast
The effectiveness and relative ...... re-a meta-regression analysis.
@en
The effectiveness and relative ...... re-a meta-regression analysis.
@nl
P2093
P2860
P1476
The effectiveness and relative ...... re-a meta-regression analysis.
@en
P2093
Joanne Easthaugh
John G F Cleland
Nick Freemantle
Simon Thackray
P2860
P304
P356
10.1016/S1388-9842(02)00041-7
P577
2002-08-01T00:00:00Z